Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Novartis Investigative Site, Skedsmokorset

Novartis Investigative Site, Kløfta

Novartis Investigative Site, Kongsvinger

Novartis Investigative Site, Stavanger

Novartis Investigative Site, Linz

Novartis Investigative Site, Wels

Novartis Investigative Site, Grieskirchen

Novartis Investigative Site, Trondheim

Novartis Investigative Site, Feldbach

Novartis Investigative Site, Aalborg

Novartis Investigative Site, Hvidovre

Novartis Investigative Site, Aarhus

Novartis Investigative Site, Copenhagen NV

Novartis Investigative Site, Odense C

Novartis Investigative Site, Almelo

Novartis Investigative Site, Harderwijk

Novartis Investigative Site, Heerlen

Novartis Investigative Site, Eindhoven

Novartis Investigative Site, Hengelo

Novartis Investigative Site, Sittard-Geleen

Novartis Investigative Site, Tubbergen

Novartis Investigative Site, Veldhoven

Novartis Investigative Site, Gothenburg

Novartis Investigative Site, Stockholm

Novartis Investigative Site, Stockholm

Novartis Investigative Site, Uddevalla